BACKGROUND: We report the long-term outcomes of patients who survived 20 years or greater after heart transplantation. METHODS: From 1985 to 2012, 386 patients underwent heart transplantation at our institution. Patient data were analyzed retrospectively for transplants performed from 1985 to 1991. The Kaplan-Meier method was used for survival analyses. RESULTS: In total, 133 patients were included. The mean age of the 20-year survivors at transplant was 43.6±11.4 years. The mean ischemic time was 71.2±34.0 minutes. The overall actuarial survival rates at 1, 10, and 20 years were 82.7%, 63.9%, and 55.6%, respectively. The most common causes of death were graft rejection (21%), malignancy (21%), infection (15%), and cardiac allograft vasculopathy (CAV, 14%). After 1, 10, and 20 years, the rejection-free survival rates were 19%, 13%, and 13%, respectively, and the malignancy-free survival rates were 99%, 67%, and 61%. The CAV-free survival rates were 97%, 48%, and 42%, respectively, and the infection-free survival rates were, respectively, 70%, 15%, and 14%. The actuarial diabetes-free survival rates at 1, 10, and 20 years were 85%, 80%, and 79%, respectively. Actuarial hypertension-free survival was 56% after 1 year and 26% after 10 and 20 years. Two patients received a second heart transplant. CONCLUSIONS: A remarkable number of patients survived 20 years or greater after heart transplantation, confirming the procedure as the gold standard for end-stage heart failure. Complications resulting from immunologic events and immunosuppressive therapy determine post-transplant mortality and morbidity. Due to improvements in immunosuppressive management in recent years, long-term survival is likely to increase.
BACKGROUND: We report the long-term outcomes of patients who survived 20 years or greater after heart transplantation. METHODS: From 1985 to 2012, 386 patients underwent heart transplantation at our institution. Patient data were analyzed retrospectively for transplants performed from 1985 to 1991. The Kaplan-Meier method was used for survival analyses. RESULTS: In total, 133 patients were included. The mean age of the 20-year survivors at transplant was 43.6±11.4 years. The mean ischemic time was 71.2±34.0 minutes. The overall actuarial survival rates at 1, 10, and 20 years were 82.7%, 63.9%, and 55.6%, respectively. The most common causes of death were graft rejection (21%), malignancy (21%), infection (15%), and cardiac allograft vasculopathy (CAV, 14%). After 1, 10, and 20 years, the rejection-free survival rates were 19%, 13%, and 13%, respectively, and the malignancy-free survival rates were 99%, 67%, and 61%. The CAV-free survival rates were 97%, 48%, and 42%, respectively, and the infection-free survival rates were, respectively, 70%, 15%, and 14%. The actuarial diabetes-free survival rates at 1, 10, and 20 years were 85%, 80%, and 79%, respectively. Actuarial hypertension-free survival was 56% after 1 year and 26% after 10 and 20 years. Two patients received a second heart transplant. CONCLUSIONS: A remarkable number of patients survived 20 years or greater after heart transplantation, confirming the procedure as the gold standard for end-stage heart failure. Complications resulting from immunologic events and immunosuppressive therapy determine post-transplant mortality and morbidity. Due to improvements in immunosuppressive management in recent years, long-term survival is likely to increase.
Authors: Grzegorz M Kubiak; Radosław Kwieciński; Agnieszka Ciarka; Andrzej Tukiendorf; Piotr Przybyłowski; Tomasz Hrapkowicz; Michał O Zembala Journal: Cardiol Res Pract Date: 2020-07-23 Impact factor: 1.866
Authors: Nicola Vistarini; Anthony Nguyen; Michel White; Normand Racine; Louis P Perrault; Anique Ducharme; Denis Bouchard; Philippe Demers; Michel Pellerin; Yoan Lamarche; Ismaïl El-Hamamsy; Geneviève Giraldeau; Guy Pelletier; Michel Carrier Journal: Can J Surg Date: 2017-09 Impact factor: 2.089
Authors: A Sammani; A M Wind; J H Kirkels; C Klöpping; M P Buijsrogge; F Z Ramjakhan; F W Asselbergs; N de Jonge Journal: Neth Heart J Date: 2017-09 Impact factor: 2.380